Loading...
| A08356 | Pages: 243 | Jul 2021 | 828 Views | | |
| Author(s) : Smita Nerkar , Onkar Sumant | Tables: 127 | Charts: 43 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Oligonucleotide Synthesis Market
Request Now !The global oligonucleotide synthesis market was valued at $5,197.50 million in 2020, and is projected to reach $26,099.90 million by 2030, registering a CAGR of 17.10% from 2021 to 2030.
Oligonucleotide synthesis is the chemical synthesis of relatively short fragments of nucleic acids with defined chemical structure (sequence). The technique is extremely useful in current laboratory practice because it provides a rapid and inexpensive access to custom-made oligonucleotides of the desired sequence. It is also useful for carrying out the molecular diagnosis in several diseases, including detection of infectious diseases, such as hepatitis, SARS-COV2 as well as for diagnosis of cancer.
Get more information on this report : Request Sample Pages
Rise in government support for synthetic biology and genome projects and robust research is a major factor that drives the growth of the oligonucleotide synthesis market. In addition, R&D expenditure in pharmaceutical and biotechnology companies to produce oligonucleotide products with increased therapeutic potential and less side effects further fuels the growth of the market. Moreover, growing applications of synthesized oligonucleotides in molecular diagnostics & clinical applications as well as rise in demand for high end customized oligos and upgradation in purification of synthetic oligonucleotide also boost the growth of the oligonucleotide synthesis market. On the contrary, the market for oligonucleotide synthesis may be hindered by the complexities associated with therapeutic oligos and challenging delivery of oligonucleotide drugs to specific targets. However, growth opportunities in emerging economies and rise in focus on personalized medicine are anticipated to create lucrative opportunity to the market.
The outbreak of COVID-19 has disrupted workflows in the healthcare sector across the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of healthcare. However, there has also been a positive effect and surge in demand for various medical services, including oligonucleotide products. Oligo products are required for developing test kits, treatments, and vaccines that target the infection caused by the novel Coronavirus. Moreover, with the increase in cases of coronavirus disease (COVID-19) and the urgency for a potential treatment, new generations of oligonucleotide drugs, including mRNA and DNA vaccines, are currently under development. For instance, in June 2020, Bio-Synthesis Inc. (US) delivered ready-to-use cocktail mixes such as the SARS-CoV-2 N1 Oligo Mix, the SARS-CoV-2 N2 Oligo Mix, and the Human RNase P (RP) Oligo Mix for COVID-19 research. Furthermore, in April 2020, TriLink BioTechnologies (a part of Maravai Lifesciences) (US) entered into a partnership with Imperial College London (UK) for the manufacturing of self-amplifying RNA (saRNA) for COVID-19 vaccine development. Moreover, during the COVID-19 pandemic, Biolegio B.V. (Netherlands) rapidly scaled up production capabilities to deliver primers and probes for RT-qPCR testing of the Coronavirus and have been supplying laboratories and customers sufficient primer and probe sets to perform millions of tests.
The global oligonucleotide synthesis market is segmented on the basis of product, application, end user, and region. On the basis of product, the market is categorized into oligonucleotide-based drugs, synthesized oligonucleotides, reagents, and equipment. By application, it is classified into therapeutic applications, research applications, and diagnostic applications. On the basis of end user, it is classified into hospitals, pharmaceutical & biotechnology companies, diagnostic laboratories, CROs and CMOs, academic research institutes. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Based on product, the oligonucleotide synthesis market is segmented into oligonucleotide-based drugs, synthesized oligonucleotides, reagents, and equipment. The intramuscular segment dominates the global market in 2020, and is anticipated to continue this trend during the forecast period. The factor that drives the growth of this segment include increase in number of FDA-approved drugs and a rich clinical pipeline of oligonucleotide-based drugs.
Get more information on this report : Request Sample Pages
On the basis of application, the oligonucleotide synthesis market is segmented into research applications and diagnostic applications. Therapeutic application segment is expected to account for the largest revenue during forecast period, owing to increase in research of therapeutic application.
On the basis of end user, it is classified into hospitals, pharmaceutical & biotechnology companies, diagnostic laboratories, CROs and CMOs, academic research institutes. Hospital segment dominated the global oligonucleotide synthesis market in 2020, and is anticipated to continue this trend during the forecast period. This is attributed to significant number of inpatient & outpatient visits in hospitals and the high requirement of oligonucleotide drugs to cater to the growing demand of patients suffering from rare diseases, neurological disorders, and infectious diseases.
Get more information on this report : Request Sample Pages
Asia-Pacific is expected to exhibit the fastest market growth during the forecast period, owing to constantly expanding healthcare infrastructure, economic development, increase in government support and investment. In addition, upsurge in cases of chronic disorders such as COVID-19, coronary disease, cancer, and others and increase in government support and investment for improving the health of people, accelerates the growth of market. For instance, in January 2020, the Department of Biotechnology (DBT) initiated the “Genome India Project” (GIP). The project aims to collect 10,000 genetic samples from citizens across India to build a reference genome. Some focus areas of this project are precision health, rare genetic disorders, mutation spectrum of genetic & complex diseases in the Indian population, genetic epidemiology of multifactorial lifestyle diseases, and translational research. Moreover, key players in this emerging region create a lucrative opportunity for oligonucleotide synthesis market. For instance, in 2020, IDT (US) opened IDT China, an official business entity in China to better serve its customer base in the region, to reach out to new customers, and provide easier access to its complete portfolio of industry-leading products, including custom DNA and RNA oligos, probes, and primers.
The key market players profiled in the report include Alnylam Pharmaceuticals, Inc., Biogen Inc., Danaher Corporation, Eurofins Scientific, Ionis Pharmaceuticals, Inc., Kaneka Corporation, LGC Limited, Merck KGAA, Sarepta Therapeutics, Inc., Thermo Fisher Scientific, Inc.
Get more information on this report : Request Sample Pages
Key Benefits For Stakeholders
Key Market Segments
By Product
By Application
By End User
By Region
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five force analysis
3.4.Top player positioning, 2020
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Increase in government investments and R&D expenditure in pharmaceutical & biotechnology companies
3.5.1.2.Surge in usage of synthesized oligonucleotides in molecular diagnostics and clinical applications
3.5.1.3.Rise in demand for high end customized oligos and upgradation in purification
3.5.2.Restraints
3.5.2.1.Complexities associated with therapeutic oligos
3.5.2.2.Challenging delivery of oligonucleotide drugs to specific targets
3.5.3.Opportunities
3.5.3.1.Growth opportunities in emerging economies
3.5.3.2.Growing focus on personalized medicine
3.5.4.Impact analysis
3.6.COVID-19 impact analysis on the oligonucleotide synthesis market
CHAPTER 4:OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT
4.1.Overview
4.1.1.Market size and forecast
4.2.Oligonucleotide-based drugs
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Synthesized oligonucleotides
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
4.4.Reagents
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country
4.5.Equipment
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast
4.5.3.Market analysis, by country
CHAPTER 5:OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Therapeutic applications
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.2.3.Market size and forecast, by Product
5.3.Research applications
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.3.3.Market size and forecast, by Product
5.4.Diagnostic applications
5.4.1.Market size and forecast
5.4.2.Market analysis, by country
5.4.3.Market size and forecast, by Product
CHAPTER 6:OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER
6.1.Overview
6.1.1.Market size and forecast
6.2.Hospitals
6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country
6.3.Pharmaceutical & biotechnology companies
6.3.1.Market size and forecast
6.3.2.Market analysis, by country
6.4.Diagnostic laboratories
6.4.1.Market size and forecast
6.4.2.Market analysis, by country
6.5.CROs and CMOs
6.5.1.Market size and forecast
6.5.2.Market analysis, by country
6.6.Academic research institutes
6.6.1.Market size and forecast
6.6.2.Market analysis, by country
CHAPTER 7:OLIGONUCLEOTIDE SYNTHESIS, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by country
7.2.2.1.U.S.
7.2.2.1.1.U.S. oligonucleotide synthesis market, by product
7.2.2.1.2.U.S. oligonucleotide synthesis market, by application
7.2.2.1.3.U.S. oligonucleotide synthesis market, by end user
7.2.2.2.Canada
7.2.2.2.1.Canada oligonucleotide synthesis, by product
7.2.2.2.2.Canada oligonucleotide synthesis market, by application
7.2.2.2.3.Canada oligonucleotide synthesis market, by end user
7.2.2.3.Mexico
7.2.2.3.1.Mexico oligonucleotide synthesis market, by product
7.2.2.3.2.Mexico oligonucleotide synthesis market, by application
7.2.2.3.3.Mexico oligonucleotide synthesis market, by end user
7.2.3.North America market size and forecast, by product
7.2.4.North America market size and forecast, by application
7.2.5.North America market size and forecast, by end user
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by country
7.3.2.1.Germany
7.3.2.1.1.Germany oligonucleotide synthesis market, by product
7.3.2.1.2.Germany oligonucleotide synthesis market, by application
7.3.2.1.3.Germany oligonucleotide synthesis market, by end user
7.3.2.2.France
7.3.2.2.1.France oligonucleotide synthesis market, by product
7.3.2.2.2.France oligonucleotide synthesis market, by application
7.3.2.2.3.France oligonucleotide synthesis market, by end user
7.3.2.3.UK
7.3.2.3.1.UK oligonucleotide synthesis market, by product
7.3.2.3.2.UK oligonucleotide synthesis market, by application
7.3.2.3.3.UK oligonucleotide synthesis market, by end user
7.3.2.4.Italy
7.3.2.4.1.Italy oligonucleotide synthesis market, by product
7.3.2.4.2.Italy oligonucleotide synthesis market, by application
7.3.2.4.3.Italy oligonucleotide synthesis market, by end user
7.3.2.5.Spain
7.3.2.5.1.Spain oligonucleotide synthesis market, by product
7.3.2.5.2.Spain oligonucleotide synthesis market, by application
7.3.2.5.3.Spain oligonucleotide synthesis market, by end user
7.3.2.6.Rest of Europe
7.3.2.6.1.Rest of Europe oligonucleotide synthesis market, by product
7.3.2.6.2.Rest of Europe oligonucleotide synthesis market, by application
7.3.2.6.3.Rest of Europe oligonucleotide synthesis market, by end user
7.3.3.Europe market size and forecast, by product
7.3.4.Europe market size and forecast, by application
7.3.5.Europe market size and forecast, by end user
7.4.Asia-Pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by country
7.4.2.1.Japan
7.4.2.1.1.Japan Oligonucleotide synthesis market, by product
7.4.2.1.2.Japan oligonucleotide synthesis market, by application
7.4.2.1.3.Japan oligonucleotide synthesis market, by end user
7.4.2.2.China
7.4.2.2.1.China Oligonucleotide synthesis market, by product
7.4.2.2.2.China oligonucleotide synthesis market, by application
7.4.2.2.3.China Oligonucleotide synthesis market, by end user
7.4.2.3.Australia
7.4.2.3.1.Australia oligonucleotide synthesis market, by product
7.4.2.3.2.Australia oligonucleotide synthesis market, by application
7.4.2.3.3.Australia oligonucleotide synthesis market, by end user
7.4.2.4.India
7.4.2.4.1.India oligonucleotide synthesis market, by product
7.4.2.4.2.India oligonucleotide synthesis market, by application
7.4.2.4.3.India oligonucleotide synthesis market, by end user
7.4.2.5.South Korea
7.4.2.5.1.South Korea oligonucleotide synthesis market, by product
7.4.2.5.2.South Korea oligonucleotide synthesis market, by application
7.4.2.5.3.South Korea Oligonucleotide synthesis market, by end user
7.4.2.6.Rest of Asia-Pacific
7.4.2.6.1.Rest of Asia-Pacific oligonucleotide synthesis market, by product
7.4.2.6.2.Rest of Asia-Pacific oligonucleotide synthesis market, by application
7.4.2.6.3.Rest of Asia-Pacific oligonucleotide synthesis market, by end user
7.4.3.Asia-Pacific market size and forecast, by product
7.4.4.Asia-Pacific market size and forecast, by application
7.4.5.Asia-Pacific market size and forecast, by end user
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by country
7.5.2.1.Brazil
7.5.2.1.1.Brazil oligonucleotide synthesis market, by product
7.5.2.1.2.Brazil oligonucleotide synthesis market, by application
7.5.2.1.3.Brazil oligonucleotide synthesis market, by end user
7.5.2.2.Saudi Arabia
7.5.2.2.1.Saudi Arabia oligonucleotide synthesis market, by product
7.5.2.2.2.Saudi Arabia oligonucleotide synthesis market, by application
7.5.2.2.3.Saudi Arabia oligonucleotide synthesis market, by end user
7.5.2.3.South Africa
7.5.2.3.1.South Africa oligonucleotide synthesis market, by product
7.5.2.3.2.South Africa oligonucleotide synthesis market, by application
7.5.2.3.3.South Africa oligonucleotide synthesis market, by end user
7.5.2.4.Rest of LAMEA
7.5.2.4.1.Rest of LAMEA oligonucleotide synthesis market, by product
7.5.2.4.2.Rest of LAMEA oligonucleotide synthesis market, by application
7.5.2.4.3.Rest of LAMEA oligonucleotide synthesis market, by end user
7.5.3.LAMEA market size and forecast, by product
7.5.4.LAMEA market size and forecast, by application
7.5.5.LAMEA market size and forecast, by end user
CHAPTER 8:COMPANY PROFILES
8.1.ALNYLAM PHARMACEUTICALS, INC.
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments
8.2.BIOGEN LIMITED
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments
8.3.CINVEN
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.4.DANAHER CORPORATION
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments
8.5.EUROFINS SCIENTIFIC
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.5.6.Key strategic moves and developments
8.6.IONIS PHARMACEUTICALS, INC.
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.6.6.Key strategic moves and developments
8.7.KANEKA CORPORATION
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments
8.8.MERCK KGAA
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments
8.9.SAREPTA THERAPEUTICS, INC.
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments
8.10.THERMO FISHER SCIENTIFIC, INC.
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and developments
LIST OF TABLES
TABLE 01.OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030 ($BILLION)
TABLE 02.OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OLIGONUCLEOTIDE-BASED DRUGS, BY REGION, 2020-2030 ($BILLION)
TABLE 03.OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020-2030 ($BILLION)
TABLE 04.OLIGONUCLEOTIDE SYNTHESIS MARKET FOR REAGENTS, BY REGION, 2020-2030 ($BILLION)
TABLE 05.OLIGONUCLEOTIDE SYNTHESIS MARKET FOR EQUIPMENT, BY REGION, 2020-2030 ($BILLION)
TABLE 06.OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030($BILLION)
TABLE 07.OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020-2030($BILLION)
TABLE 08.OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY PRODUCT, 2020-2030($BILLION)
TABLE 09.OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020-2030($BILLION)
TABLE 10.OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY PRODUCT, 2020-2030($BILLION)
TABLE 11.OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2020-2030($BILLION)
TABLE 12.OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTICS APPLICATIONS, BY PRODUCT, 2020-2030($BILLION)
TABLE 13.OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030($MILLION)
TABLE 14.OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY REGION, 2020-2030($MILLION)
TABLE 15.OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020-2030($MILLION)
TABLE 16.OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2020-2030($MILLION)
TABLE 17.OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS AND CMOS, BY REGION, 2020-2030($MILLION)
TABLE 18.OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2020-2030($MILLION)
TABLE 19.OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION, 2020-2030($MILLION)
TABLE 20.NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2020-2030($MILLION)
TABLE 21.U.S. OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 22.U.S. OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 23.U.S. OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 24.CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 25.CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 26.CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 27.MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 28.MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 29.MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 30.NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 31.NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET , BY APPLICATION, 2020-2030
TABLE 32.NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 33.EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2020-2030($MILLION)
TABLE 34.GERMANY OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 35.GERMANY OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 36.GERMANY OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 37.FRANCE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 38.FRANCE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 39.FRANCE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 40.UK OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 41.UK OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 42.UK OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 43.ITALY OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 44.ITALY OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 45.ITALY OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 46.SPAIN OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 47.SPAIN OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 48.SPAIN OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 49.REST OF EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 50.REST OF EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 51.REST OF EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 52.EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 53.EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 54.EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 55.ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2020-2030($MILLION)
TABLE 56.JAPAN OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 57.JAPAN OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 58.JAPAN OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 59.CHINA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 60.CHINA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 61.CHINA OLIGONUCLEOTIDE SYNTHESIS, BY END USER, 2020-2030
TABLE 62.AUSTRALIA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 63.AUSTRALIA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 64.AUSTRALIA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 65.INDIA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 66.INDIA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 67.INDIA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 68.SOUTH KOREA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 69.SOUTH KOREA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 70.SOUTH KOREA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 71.REST OF ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 72.REST OF ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 73.REST OF ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 74.ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 75.ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 76.ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 77.LAMEA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2020-2030($MILLION)
TABLE 78.BRAZIL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 79.BRAZIL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 80.BRAZIL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 81.SAUDI ARABIA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 82.SAUDI ARABIA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 83.SAUDI ARABIA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 84.SOUTH AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 85.SOUTH AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 86.SOUTH AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 87.REST OF LAMEA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 88.REST OF LAMEA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 89.REST OF LAMEA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 90.LAMEA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 91.LAMEA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 92.LAMEA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 93.ALNYLAM: COMPANY SNAPSHOT
TABLE 94.ALNYLAM: OPERATING BUSINESS SEGMENTS
TABLE 95.ALNYLAM: PRODUCT PORTFOLIO
TABLE 96.ALNYLAM: KEY DEVELOPMENTS
TABLE 97.BIOGEN: COMPANY SNAPSHOT
TABLE 98.BIOGEN: OPERATING SEGMENTS
TABLE 99.BIOGEN: PRODUCT PORTFOLIO
TABLE 100.BIOGEN: KEY DEVELOPMENTS
TABLE 101.CINVEN: COMPANY SNAPSHOT
TABLE 102.CINVEN: OPERATING SEGMENTS
TABLE 103.CINVEN: PRODUCT PORTFOLIO
TABLE 104.DANAHER: COMPANY SNAPSHOT
TABLE 105.DANAHER: PRODUCT SEGMENTS
TABLE 106.DANAHER: PRODUCT PORTFOLIO
TABLE 107.DANAHER: KEY DEVELOPMENTS
TABLE 108.EUROFINS: COMPANY SNAPSHOT
TABLE 109.EUROFINS: PRODUCT PORTFOLIO
TABLE 110.EUROFINS: KEY DEVELOPMENTS
TABLE 111.IONIS: COMPANY SNAPSHOT
TABLE 112.IONIS: OPERATING BUSINESS SEGMENTS
TABLE 113.IONIS: PRODUCT PORTFOLIO
TABLE 114.IONIS: KEY DEVELOPMENTS
TABLE 115.KANEKA: COMPANY SNAPSHOT
TABLE 116.KANEKA: OPERATING SEGMENTS
TABLE 117.KANEKA: PRODUCT PORTFOLIO
TABLE 118.KANEKA: KEY DEVELOPMENTS
TABLE 119.MERCK: COMPANY SNAPSHOT
TABLE 120.MERCK: OPERATING SEGMENTS
TABLE 121.MERCK: PRODUCT PORTFOLIO
TABLE 122.MERCK: KEY DEVELOPMENTS
TABLE 123.SAREPTA: COMPANY SNAPSHOT
TABLE 124.SAREPTA: OPERATING BUSINESS SEGMENTS
TABLE 125.SAREPTA: PRODUCT PORTFOLIO
TABLE 126.SAREPTA: KEY DEVELOPMENTS
TABLE 127.THERMO FISHER: COMPANY SNAPSHOT
TABLE 128.THERMO FISHER: OPERATING SEGMENTS
TABLE 129.THERMO FISHER: PRODUCT PORTFOLIO
TABLE 130.THERMO FISHER: KEY DEVELOPMENTS
LIST OF FIGURES
FIGURE 01.OLIGONUCLEOTIDE SYNTHESIS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018-2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2021
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018-2021
FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE THREAT OF SUBSTITUTES
FIGURE 09.MODERATE THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE INTENSITY OF RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.COMPARATIVE ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OLIGONUCLEOTIDE-BASED DRUGS, BY COUNTRY, 2020 & 2030 ($BILLION)
FIGURE 14.COMPARATIVE ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020 & 2030 ($BILLION)
FIGURE 15.COMPARATIVE ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET FOR REAGENTS, BY COUNTRY, 2020 & 2030 ($BILLION)
FIGURE 16.COMPARATIVE ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET FOR EQUIPMENT, BY COUNTRY, 2020 & 2030 ($BILLION)
FIGURE 17.COMPARATIVE ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020 & 2030 ($BILLION)
FIGURE 18.COMPARATIVE ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020 & 2030 ($BILLION)
FIGURE 19.COMPARATIVE ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020 & 2030 ($BILLION)
FIGURE 20.COMPARATIVE ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 21.COMPARATIVE ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 22.COMPARATIVE ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 23.COMPARATIVE ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS AND CMOS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 24.COMPARATIVE ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 25.ALNYLAM: NET SALES, 2018–2020 ($MILLION)
FIGURE 26.BIOGEN: NET SALES, 2018–2020 ($MILLION)
FIGURE 27.DANAHER: NET SALES, 2018–2020 ($MILLION)
FIGURE 28.DANAHER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 29.DANAHER: REVENUE SHARE BY REGION, 2020(%)
FIGURE 30.EUROFINS: NET SALES, 2018–2020 ($MILLION)
FIGURE 31.EUROFINS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 32.IONIS: NET SALES, 2018–2020 ($MILLION)
FIGURE 33.IONIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 34.KANEKA: NET SALES, 2018–2020 ($MILLION)
FIGURE 35.KANEKA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 36.KANEKA: REVENUE SHARE BY REGION, 2020(%)
FIGURE 37.MERCK: NET SALES, 2018–2020 ($MILLION)
FIGURE 38.MERCK: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 39.MERCK: REVENUE SHARE BY REGION, 2020(%)
FIGURE 40.SAREPTA: NET SALES, 2018–2020 ($MILLION)
FIGURE 41.THERMO FISHER: NET SALES, 2018–2020 ($MILLION)
FIGURE 42.THERMO FISHER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 43.THERMO FISHER: REVENUE SHARE BY REGION, 2020(%)
Chemical synthesis of short fragment of nucleic acids is defined as oligonucleotide synthesis. The technique is extremely useful in current laboratory practice because it provides a rapid and inexpensive access to custom-made oligonucleotides of the desired sequence. Oligonucleotides provides many applications such as DNA sequencing, synthesis of artificial genes, and diagnosis of many diseases associated with genetic mutation.
Increase in government investments and R&D expenditure in pharmaceutical and biotechnology companies, surge in usage of synthesized oligonucleotides in molecular diagnostics & clinical applications, and rise in the demand for high-end customized oligos and upgradation in purification are some factors that drive the growth of the market. Moreover, growth opportunities in emerging economies and rise in focus on personalized medicines create a lucrative opportunity for the market. However, complexities associated with therapeutic oligos and complication in delivery of oligonucleotide drugs to specific targets restrain the growth of the market.
Oligonucleotide-based drug is expected to remain dominant during the forecast period, owing to increase in number of FDA-approved drugs and a rich clinical pipeline of oligonucleotide-based drugs. Moreover, North America is expected to offer lucrative opportunities to the key players during the forecast period, due to growing R&D in life sciences, increase in focus on improving the safety & quality of healthcare, growth in demand for high-quality research tools for data reproducibility, and increase in focus on developing personalized therapeutics.
A. The total market value of Oligonucleotide synthesis market is $5197.50 million in 2020.
A. The forcast period for Oligonucleotide synthesis market is 2021 to 2030
A. The market value of Oligonucleotide synthesis market in 2021 is $6300.00 million.
A. The base year is 2020 in Oligonucleotide synthesis market
A. Top companies such as Thermo Fisher, Merck KGAA, Biogen, Eurofins, Kaneka Corporation, Danaher Corporation held a high market position in 2020.
A. Oligonucleotide-based drugs segment is the most influencing segment owing to increasing number of FDA-approved drugs and a rich clinical pipeline of oligonucleotide-based drugs.
A. Increasing government investments and R&D expenditure in pharmaceutical and biotechnology companies, increase in usage of synthesized oligonucleotides in molecular diagnostics & clinical applications and increase in demand for high end customized oligos and upgradation in purification are some factors which drive the growth of market.
A. Asia-Pacific is expected to experience the highest growth rate during the forecast period, owing to constantly expanding healthcare infrastructure, economic development, increase in government support and investment. In addition, upsurge in cases of chronic disorders such as Covid-19, coronary disease, cancer and among others and increasing government support and investment for improving the health of people
A. chemical synthesis of short fragment of nucleic acids is defined as oligonucleotide synthesis.
A. Oligonucleotides provides many applications such as DNA sequencing, synthesis of artificial genes, and diagnosis of many diseases associated with genetic mutation.
Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Buy Now *Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
